中华眼底病杂志

中华眼底病杂志

渗出型老年性黄斑变性治疗中抗血管内皮生长因子药物治疗中更换应用的研究进展

查看全文

玻璃体腔注射抗血管内皮生长因子(VEGF)药物治疗渗出型老年性黄斑变性(wAMD)的有效性已被证实,其药物包括贝伐单抗、雷珠单抗等单克隆抗体类药物和阿柏西普、康柏西普等融合蛋白类药物。但仍有部分患者经抗VEGF药物治疗后疗效不佳,包括初治无应答或应答不佳,甚至治疗过程中病情反复。由于抗VEGF药物的作用靶点及分子特点不同,抗VEGF药物的更换应用以及给药模式、给药剂量、给药间歇期的调整等,成为疗效欠佳的应对策略。但现存的众多研究所得结果不尽相同,视网膜解剖结构的恢复获益更多,视力改善相对困难。何种治疗方案获益最大,仍有待大样本临床随机对照研究和长期随访进一步探索。

Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs, including monoclonal antibodies (such as bevacizumab and ranibizumab) and fusion protein agents (such as aflibercept and conbercept) have been proven to be effective in the treatment of wet age-related macular degeneration (wAMD). However, there are still some patients with poor efficacy, such as no response to initial treatment or poor response, and even relapse during the course of treatment. In view of the different targets and molecular characteristics of anti-VEGF drugs, the switch of anti-VEGF drugs and the adjustment of delivery pattern, dosages and intervals have been the strategies to cope with the poor efficacy in clinic. However, there are some differences in the results of current studies. Overall, the recovery of retinal anatomical outcome achieves more benefits, and it is relatively difficult to improve visual acuity. To determine which regimen would get the biggest benefits, a large number of randomized controlled clinical trials and long study period will be needed.

关键词: 湿性黄斑变性/药物疗法; 血管生成抑制剂/治疗应用; 抗体,单克隆,人/治疗应用; 综述

Key words: Wet macular degeneration/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies, monoclonal, humanized/therapeutic use; Review

引用本文: 杜雪利, 李文博, 胡博杰. 渗出型老年性黄斑变性治疗中抗血管内皮生长因子药物治疗中更换应用的研究进展. 中华眼底病杂志, 2018, 34(5): 498-503. doi: 10.3760/cma.j.issn.1005-1015.2018.05.021 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Votruba M, Gregor Z. Neovascular age-related macular degeneration: present and future treatment options[J]. Eye (Lond), 2001, 15(Pt 3): 424-429. DOI: 10.1038/eye.2001.147.
2. Husain D, Ambati B, Adamis AP, et al. Mechanisms of age-related macular degeneration[J]. Ophthalmol Clin North Am, 2002, 15(1): 87-91.
3. Doggrell SA. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration[J]. Expert Opin Pharmacother, 2005, 6(8): 1421-1423. DOI: 10.1517/14656566.6.8.1421.
4. Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration[J]. Drug Des Devel Ther, 2015, 9: 2311-2320. DOI: 10.2147/DDDT.S67536.
5. Sarwar S, Clearfield E, Soliman MK, et al. Aflibercept for neovascular age-related macular degeneration[J/CD]. Cochrane Database Syst Rev, 2016, 2: CD011346. DOI: 10.1002/14651858.CD011346.pub2.
6. Park DH, Sun HJ, Lee SJ.A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration [J/OL].Int Ophthalmol, 2016, 2016: E1[2016-11-08]. https://link.springer.com/article/10.1007%2Fs10792-016-0391-4.DOI: 10.1007/s10792-016-0391-4.[published online ahead of print].
7. Jin E, Bai Y, Luo L, et al. Serum levels of vascular endothelial growth factor before and after intravitreal injection of ranibizumab or conbercept for neovascular age-related macular degeneration[J]. Retina, 2017, 37(5): 971-977. DOI: 10.1097/IAE.0000000000001274.
8. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration [J]. Ophthalmology, 2007, 114(9): 1702-1712. DOI: 10.1016/j.ophtha.2007.02.021.
9. Michalewski J, Nawrocki J, Trębińska M, et al. Switch to a single dose of aflibercept in bevacizumab nonresponders with AMD[J]. Can J Ophthalmol, 2014, 49(5): 431-435. DOI: 10.1016/j.jcjo.2014.07.012.
10. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation[J]. Br J Ophthalmol, 2012, 96(1): 14-20. DOI: 10.1136/bjo.2011.204685.
11. Leveziel N, Pelat T, Watier H, et al. Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration[J]. Ophthalmologica, 2014, 232(1): 53-56. DOI: 10.1159/000360186.
12. Funk M, Karl D, Georgopoulos M, et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab[J]. Ophthalmology, 2009, 116(12): 2393-2399. DOI: 10.1016/j.ophtha.2009.05.039.
13. Lazzeri S, Nardi M, Bocci G. Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward?[J]. Pharmacogenomics, 2013, 14(11): 1239-1242. DOI: 10.2217/pgs.13.100.
14. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration[J]. Ophthalmology, 2014, 121(1): 188-192. DOI: 10.1016/j.ophtha.2013.08.035.
15. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration[J]. Retina, 2013, 33(8): 1605-1612. DOI: 10.1097/IAE.0b013e31828e8551.
16. Fassnacht-Riederle H, Becker M, Graf N, et al. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD[J]. Graefe’s Arch Clin Exp Ophthalmol, 2014, 252(11): 1705-1709. DOI: 10.1007/s00417-014-2589-3.
17. Singh RP, Srivastava S, Ehlers JP, et al. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis[J]. Br J Ophthalmol, 2014, 98 Suppl 1: S22-27. DOI: 10.1136/bjophthalmol-2013-304798.
18. Heussen FM, Shao Q, Ouyang Y, et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration[J]. Graefe’s Arch Clin Exp Ophthalmol, 2014, 252(6): 909-915. DOI: 10.1007/s00417-013-2553-7.
19. Gillies MC, Daien V, Nguyen V, et al. Re: Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, et al.: Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials (Ophthalmology 2016;123: 1751-1761)[J]. Ophthalmology, 2017, 124(3): 31-32. DOI: 10.1016/j.ophtha.2016.05.054.
20. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab[J]. Eye (Lond), 2013, 27(5): 663-667. DOI: 10.1038/eye.2013.31.
21. Seguin-Greenstein S, Lightman S, Tomkins-Netzer O, et al. A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept[J/OL]. J Ophthalmol, 2016, 2016: 4095852[2016-03-06]. http://dx.doi.org/10.1155/2016/4095852.DOI:10.1155/2016/4095852.
22. Aghdam KA, Pielen A, Framme C, et al. Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results[J]. Eur J Ophthalmol, 2016, 26(5): 473-478.DOI: 10.5301/ejo.5000757.
23. Gharbiya M, Iannetti L, Parisi F, et al. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration[J/OL]. Biomed Res Int, 2014, 2014: 273754[2014-05-07].http://dx.doi.org/10.1155/2014/273754. DOI: 10.1155/2014/273754.
24. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration[J]. Am J Ophthalmol, 2013, 156 (1): 29-35.DOI: 10.1016/j.ajo.2013.03.030.
25. Grewal DS, Gill MK, Sarezky D, et al. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results[J]. Eye (Lond), 2014, 28(7): 895-899. DOI: 10.1038/eye.2014.101.
26. Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab[J]. Am J Ophthalmol, 2013, 156 (1): 15-22. DOI: 10.1016/j.ajo.2013.02.017.
27. Ferrone PJ, Anwar F, Naysan J, et al. Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration[J]. Br J Ophthalmol, 2014, 98 Suppl 1: S17-21. DOI: 10.1136/bjophthalmol-2013-304474.
28. Hall LB, Zebardast N, Huang JJ, et al. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients[J]. J Ocul Pharmacol Ther, 2014, 30(4): 346-352. DOI: 10.1089/jop.2013.0188.
29. Cho H, Shah CP, Weber M, et al. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab[J]. Br J Ophthalmol, 2013, 97(8): 1032-1035. DOI: 10.1136/bjophthalmol-2013-303344.
30. Waizel M, Rickmann A, Blanke BR, et al. Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD[J]. Eur J Ophthalmol, 2016, 26(5): 469-472. DOI: 10.5301/ejo.5000781.
31. Despreaux R, Cohen SY, Semoun O, et al. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice[J]. Graefe’s Arch Clin Exp Ophthalmol, 2016, 254(4): 639-644. DOI: 10.1007/s00417-015-3084-1.
32. Stepien KE, Rosenfeld PJ, Puliafito CA, et al. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration[J]. Retina, 2009, 29(8): 1067-1073. DOI: 10.1097/IAE.0b013e3181b1bb06.
33. Vottonen P, Kankaanpää E. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model[J]. Acta Ophthalmol, 2016, 94(7): 652-656. DOI: 10.1111/aos.13185.
34. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration[J/CD]. Cochrane Database Syst Rev, 2014 (8): CD005139.DOI: 10.1002/14651858.CD005139.pub3.
35. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev, 2014 (9): CD011230.DOI: 10.1002/14651858.CD011230.pub2.
36. Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis[J]. JAMA Ophthalmol, 2014, 132(11): 1317-1326. DOI: 10.1001/jamaophthalmol.2014.2333.
37. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al.Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema[J].N Engl J Med, 2015, 372(13): 1193-1203. DOI: 10.1056/NEJMoa1414264.
38. Almony A, Mansouri A, Shah GK, et al. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab[J]. Can J Ophthalmol, 2011, 46(2): 182-185.DOI: 10.3129/i10-095.
39. Mantel I, Niderprim SA, Gianniou C, et al. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen[J]. Br J Ophthalmol, 2014, 98(9): 1192-1196. DOI: 10.1136/bjophthalmol-2013-304556.
40. Takayama K, Kaneko H, Sugita T, et al. One-year outcomes of 1+pro re nata versus 3+pro re nata intravitreal aflibercept injection for neovascular age-related macular degeneration[J]. Ophthalmologica, 2017, 237(2): 105-110. DOI: 10.1159/000461785.
41. Ricci F, Parravano M, Regine F, et al. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy[J]. Eye (Lond), 2017, 31(1): 163-164. DOI: 10.1038/eye.2016.215.
42. Si T, Zhang L, Li G, et al. Experimental design and instability analysis of coaxial electrospray process for microencapsulation of drugs and imaging agents[J/OL]. J Biomed Opt, 2013, 18(7): 075003[2013-07-17]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719177/.DOI: 10.1117/1.JBO.18.7.075003.
43. 汪鹭, 彭惠. 治疗湿性年龄相关性黄斑变性的抗VEGF药物研究进展[J].国际眼科杂志, 2016, 16(10): 1847-1851. DOI: 10.3980/j.issn.1672-5123.2016.10.14.Lu W, Hui P.The progress of anti-VEGF drugs in the treatment of neovascular age-related macular degeneration[J].Inte J Ophthalmol, 2016, 16(10): 1847-1851. DOI: 10.3980/j.issn.1672-5123.2016.10.14.
44. Wykoff CC, Brown DM, Croft DE, et al. Two year save outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD[J]. Ophthalmology, 2013, 120(9): 1945-1946. DOI: 10.1016/j.ophtha.2013.06.030.
45. Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)[J]. Eye (Lond), 2012, 26(9): 1181-1187. DOI: 10.1038/eye.2012.174.
46. Lai TY, Liu DT, Chan KP, et al. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial[J]. Retina, 2009, 29(9): 1218-1226. DOI: 10.1097/IAE.0b013e3181b32c45.
47. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)[J]. Retina, 2012, 32(3): 434-457. DOI: 10.1097/IAE.0B013E31822C290F.
48. Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review[J]. Drug Des Devel Ther, 2016, 10: 1857-1867. DOI: 10.2147/DDDT.S97653.
49. Shiragami C, Ono A, Kobayashi M, et al. Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration[J]. Medicine (Baltimore), 2014, 93(18): 116. DOI: 10.1097/MD.0000000000000116.
50. Inoue M, Kadonosono K, Arakawa A, et al. Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration[J]. Jpn J Ophthalmol, 2015, 59(3): 173-178. DOI: 10.1007/s10384-015-0374-4.
51. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin)[J]. Retina, 2006, 26(3): 262-269.
52. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits[J]. Retina, 2007, 27(9): 1260-1266. DOI: 10.1097/IAE.0b013e318134eecd.
53. 戴虹,卢颖毅.影响抗VEGF药物治疗湿性AMD疗效的因素和对策[J].中华实验眼科杂志, 2016, 34(1): 1-4. DOI: 10.3760/cma.j.issn.2095-0160.2016.01.001.Dai H,Lu YY.Influence factors and strategies of anti-VEGF therapy for wet AMD [J]. Chin J Exp Ophthalmol, 2016, 34(1): 1-4.DOI: 10.3760/cma.j.issn.2095-0160.2016.01.001.
54. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy[J]. Am J Ophthalmol, 2009, 148(1): 70-78.DOI: 10.1016/j.ajo.2009.02.012.
55. Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?[J]. Prog Retin Eye Res, 2010, 29(1): 19-29.DOI: 10.1016/j.preteyeres.2009.10.001.
56. Matsumiya W, Honda S, Bessho H, et al. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy[J/OL]. J Ophthalmol, 2011, 2011: 742020[2011-06-12]. http://dx.doi.org/10.1155/2011/742020.DOI: 10.1155/2011/742020.
57. Sonoda S, Sakamoto T, Otsuka H, et al. Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab[J]. BMC Ophthalmol, 2013, 13: 43. DOI: 10.1186/1471-2415-13-43.
58. Chamberlain M, Baird P, Dirani M, et al. Unraveling a complex genetic disease: age-related macular degeneration[J]. Surv Ophthalmol, 2006, 51(6): 576-586. DOI: 10.1016/j.survophthal.2006.08.003.
59. Shin JY, Woo SJ, Ahn J, et al. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography [J].Korean J Ophthalmol, 2013, 27(6): 425-432.DOI: 10.3341/kjo.2013.27.6.425.
60. Cheng S, Leng T. Factors associated with poor response to aflibercept after switching from ranibizumab or bevacizumab in neovascular age-related macular degeneration[J]. Ophthalmic Surg Lasers Imaging Retina, 2016, 47(5): 458-465. DOI: 10.3928/23258160-20160419-09.
61. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results[J]. Ophthalmology, 2012, 119(7): 1388-1398.DOI: 10.1016/j.ophtha.2012.03.053.
62. van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy[J]. Br J Ophthalmol, 2012, 96(4): 587-590. DOI: 10.1136/bjophthalmol-2011-301005.
63. Hwang JC, Del Priore LV, Freund KB, et al. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration[J]. Ophthalmic Surg Lasers Imaging, 2011, 42(1): 6-11. DOI: 10.3928/15428877-20100924-01.
64. Moraru A, Pinzaru G, Motoc A, et al. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD[J]. Rom J Ophthalmol, 2017, 61(3): 207-211.
65. Waizel M, Todorova MG, Masyk M, et al. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD[J].BMC Ophthalmol, 2017, 17(1): 79. DOI: 10.1186/s12886-017-0471-x.